 NEW YORK, July 26, 2021 PRNewswire -- Synaptogenix, Inc. Nasdaq: SNPX, an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the Alzheimers Association International Conference AAIC is now available entitled Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimers Disease AD Patients: A Regenerative Therapeutic Strategy. Recent further analyses of pre-specified cohort results revealed clear evidence of Bryostatin therapeutic efficacy for advanced AD patients. 